Bal Pharma Limited Total Assets

Latest as of March 2026: Rs3.76 Billion INR ≈ $40.61 Million USD

Bal Pharma Limited total assets. Based on the latest financial reports, Bal Pharma Limited (BALPHARMA) holds total assets worth Rs3.76 Billion INR (≈ $40.61 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Bal Pharma Limited market cap and net worth for the company's overall valuation and market capitalisation.

Total Assets of Bal Pharma Limited (2006–2026)

Total assets of Bal Pharma Limited from 2006 to 2026. This chart illustrates how Bal Pharma Limited's total assets have evolved over time, based on quarterly financial data. See BALPHARMA stock price and chart for real-time trading data and today's change.

Bal Pharma Limited - Asset Composition Analysis

Bal Pharma Limited Total Assets Breakdown (March 2026)

Bal Pharma Limited total assets breakdown as of March 2026. Bal Pharma Limited's total assets of Rs3.76 Billion consist of 69.8% current assets and 30.2% non-current assets.

Asset Category Amount (INR) % of Total Assets
Cash & Equivalents Rs0.00 1.9%
Accounts Receivable Rs947.98 Million 25.2%
Inventory Rs1.16 Billion 31.0%
Property, Plant & Equipment Rs0.00 0.0%
Intangible Assets Rs134.22 Million 3.6%
Goodwill Rs38.27 Million 1.0%

Asset Composition Trend (2006–2026)

This chart illustrates how Bal Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BALPHARMA working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Bal Pharma Limited's current assets represent 69.8% of total assets in 2026, an increase from 66.9% in 2006.
  • Cash Position: Cash and equivalents constituted 1.9% of total assets in 2026, down from 6.0% in 2006.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2006.
  • Asset Diversification: The largest asset category is inventory at 31.0% of total assets.

Bal Pharma Limited Competitors by Total Assets

Key competitors of Bal Pharma Limited based on total assets are shown below.

Company Country Total Assets
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
China CN¥68.33 Billion
Sandoz Group AG
SW:SDZ
Switzerland CHF22.86 Billion
H Lundbeck A/S
CO:HLUN-B
Denmark Dkr54.01 Billion
Changchun High & New Technology Industries Group Inc
SHE:000661
China CN¥30.77 Billion
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
China CN¥17.01 Billion
Kangmei Pharmaceutical Co Ltd
SHG:600518
China CN¥13.68 Billion
Viyash Scientific Limited
NSE:SEQUENT
India Rs17.26 Billion
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
China CN¥5.11 Billion

Bal Pharma Limited - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.05 1.07 1.08
Quick Ratio 0.59 0.60 0.68
Cash Ratio 0.00 0.04 0.00
Working Capital Rs130.06 Million Rs153.72 Million Rs116.14 Million

Bal Pharma Limited - Advanced Valuation Insights

This section examines the relationship between Bal Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.08
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) 11.9%
Total Assets Rs3.76 Billion
Market Capitalization $14.14 Million USD

Valuation Analysis

Below Book Valuation: The market values Bal Pharma Limited's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Bal Pharma Limited's assets grew by 11.9% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Bal Pharma Limited (2006–2026)

The table below shows the annual total assets of Bal Pharma Limited from 2006 to 2026.

Year Total Assets Change
2026-03-31 Rs3.76 Billion
≈ $40.61 Million
+11.87%
2025-03-31 Rs3.36 Billion
≈ $36.30 Million
+5.06%
2024-03-31 Rs3.20 Billion
≈ $34.56 Million
+2.03%
2023-03-31 Rs3.13 Billion
≈ $33.87 Million
+20.20%
2022-03-31 Rs2.61 Billion
≈ $28.18 Million
+8.52%
2021-03-31 Rs2.40 Billion
≈ $25.96 Million
+0.71%
2020-03-31 Rs2.38 Billion
≈ $25.78 Million
-8.77%
2019-03-31 Rs2.61 Billion
≈ $28.26 Million
+3.77%
2018-03-31 Rs2.52 Billion
≈ $27.23 Million
+9.38%
2017-03-31 Rs2.30 Billion
≈ $24.90 Million
+9.09%
2016-03-31 Rs2.11 Billion
≈ $22.82 Million
+28.78%
2015-03-31 Rs1.64 Billion
≈ $17.72 Million
+5.89%
2014-03-31 Rs1.55 Billion
≈ $16.73 Million
+3.27%
2013-03-31 Rs1.50 Billion
≈ $16.20 Million
+6.14%
2012-03-31 Rs1.41 Billion
≈ $15.27 Million
+4.33%
2011-03-31 Rs1.35 Billion
≈ $14.63 Million
+8.94%
2010-03-31 Rs1.24 Billion
≈ $13.43 Million
+2.19%
2009-03-31 Rs1.22 Billion
≈ $13.14 Million
+11.66%
2008-03-31 Rs1.09 Billion
≈ $11.77 Million
+20.23%
2007-03-31 Rs905.28 Million
≈ $9.79 Million
+2.75%
2006-03-31 Rs881.03 Million
≈ $9.53 Million
--

About Bal Pharma Limited

NSE:BALPHARMA India Drug Manufacturers - Specialty & Generic
Market Cap
$14.14 Million
Rs1.31 Billion INR
Market Cap Rank
#25999 Global
#1442 in India
Share Price
Rs82.15
Change (1 day)
+0.43%
52-Week Range
Rs60.42 - Rs114.45
All Time High
Rs151.23
About

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Az… Read more